Tagged with BIO

USA Monica Weldon, a seasoned rare disease patient advocate in the US, now serves as the lead strategic analyst for the life science industry base policy at Leidos, a technology solutions firm. Here, she explains the rationale behind the Biden administration’s Executive Order 14081 from 2022, as well as its impact…

China A roundup of some of the top stories coming out of China’s pharma industry, including AstraZeneca’s USD 1.92 billion deal with CSPC; Bayer’s new Shanghai incubator; Genentech’s purchase of Regor Pharmaceuticals’ breast cancer portfolio; Shanghai Fosun Pharmaceutical’s African manufacturing expansion, and CanSino’s USD 17 million polio vaccine grant from the…

Switzerland Kari Sarvanto outlines his journey from leading PRIMEX to establishing CRAB, a preclinical oncology company focused on non-toxic cancer treatments. Sarvanto highlights his strategic leadership background, the innovative approach of targeting metabolic dysfunctions in cancer, and the promising progress of their lead drug, CRB091, particularly in treating aggressive cancers like…

USA In a country characterised by its racial and ethnic diversity, but where less than 5 percent of clinical trial data includes racial and ethnic factors, clinical trial diversity has become a key issue for the US FDA. Drug and medical device makers recognise the importance of diversity but find their…

Hong Kong Hong Kong has grand plans to become one of Asia’s leading clinical trial hubs. Important regulatory upgrades and increased integration with mainland China via the Greater Bay Area initiative – including a new dedicated GBA Clinical Trial Institute at the Hong Kong/mainland border – mean that this is not just…

Mexico Organon’s recently-appointed LAMEX Cluster Head Julio Conejero lays out how Organon is committed to improving women’s health and addressing unmet needs through its portfolio. This mission aligns with the rise of female leadership in Latin America and the broader movement towards women’s empowerment. Now based in Mexico – which accounts…

France At the 13th annual meeting of French life sciences think tank, G5 Santé – which represents the leaders of eight major French health and life sciences companies, including bioMérieux, Sanofi, Ipsen, and Pierre Fabre – arguments were made for increasing efficiency in a healthcare system that is “on its last…

Switzerland Thomas Wirth shares insights into Biomed’s strategic focus on the Swiss pharmaceutical market, offering comprehensive services from regulatory support to market access for RX and OTC products. He discusses Biomed’s commitment to long-term partnerships, technological advancements, and driving operational efficiency to stay competitive.   At Biomed, we prioritize delivering value…

Switzerland Swiss Biotech’s Michael Altorfer explains how Switzerland’s biotech industry continues to grow, driven by startups and SMEs and supported by strong international collaborations across the entire value chain. He outlines how Swissmedic’s proactive approach to advanced therapies and participation in the Access Consortium enables faster and more efficient drug approval…

China A roundup of some of the biggest China pharma industry stories, including the progress of the US Biosecure Act targeting Chinese biotechs; Innovent’s obesity and type 2 diabetes contender’s positive phase III trial results; the strategic partnership between Sino Biological and BioGeometry; CSL’s sale of its China-based plasma collection operations…

Japan The Japan Exchange Group (JPX) is a key platform for both established companies and emerging bio ventures in Japan. Recently, it has focused on fostering innovation and growth in sectors like biotechnology through its Growth Market segment. This market is specifically designed for early-stage companies, providing them with an avenue…

Hong Kong It has been an extremely challenging couple of years for Hong Kong’s financial sector, including for the wealth of biotech companies listed in the city, but fundamentals remain strong, and the green shoots of recovery are starting to be seen.   While biotech has historically been a high-risk, high-reward sector,…